Form 4: CRISPR Therapeutics CFO Granted 20,000 Restricted Stock Units

CRISPR Therapeutics AG's Chief Financial Officer, Raju Prasad, was granted 20,000 Restricted Stock Units, vesting fully on May 30, 2028.

Summary

• Raju Prasad, Chief Financial Officer of CRISPR Therapeutics AG (CRSP), was granted 20,000 Restricted Stock Units (RSUs).
• The grant date for these RSUs was May 30, 2025.
• Each restricted stock unit represents a contingent right to receive one common share of CRSP.
• The RSUs will vest 100% on May 30, 2028.
• Following this transaction, Mr. Prasad beneficially owns 20,000 derivative securities (RSUs) directly.

Sentiment

Score: 7

Explanation: The grant of equity to a key executive is generally a positive signal for retention and alignment of interests, though it's a routine compensation event rather than a major strategic announcement.

Positives

• The grant of 20,000 Restricted Stock Units to the Chief Financial Officer aligns management's incentives with long-term shareholder value creation.
• Equity compensation for key executives like the CFO is a common practice to retain talent and encourage performance.

Future Outlook

The RSU grant with a three-year vesting period indicates a long-term commitment by the company to retain its Chief Financial Officer and aligns his future compensation with the company's performance through May 2028.

Industry Context

Equity grants, particularly Restricted Stock Units, are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries, aiming to align executive interests with long-term company performance and shareholder value.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to a Chief Financial Officer is a common compensation practice across the biotechnology and broader corporate sectors, similar to practices at companies like Vertex Pharmaceuticals or Moderna, which frequently use equity to incentivize and retain key executives.
• The vesting schedule of 100% after three years (May 30, 2028) is a typical long-term incentive structure, comparable to vesting schedules seen in similar RSU grants at peer companies, designed to encourage executive retention and focus on sustained growth.

Corporate Governance

Stakeholder Impact

• Shareholders: The RSU grant aligns the CFO's financial interests with long-term shareholder value creation, as the value of the RSUs is tied to the company's stock performance.
• Employees: This grant is part of the executive compensation structure, which can set a precedent or standard for other employee incentive programs, potentially boosting morale and retention.

Key Dates

Recommendation

Keywords

CRISPR Therapeutics, CRSP, Restricted Stock Units, RSU, Equity Compensation, Executive Compensation, Form 4, Insider Transaction, Raju Prasad, Chief Financial Officer